nodes	percent_of_prediction	percent_of_DWPC	metapath
Sirolimus—FGF2—epilepsy syndrome	0.195	0.511	CbGaD
Sirolimus—MTOR—epilepsy syndrome	0.159	0.417	CbGaD
Sirolimus—ABCB1—epilepsy syndrome	0.0274	0.0717	CbGaD
Sirolimus—CYP3A5—Oxcarbazepine—epilepsy syndrome	0.0178	0.0526	CbGbCtD
Sirolimus—CYP3A7-CYP3A51P—Carbamazepine—epilepsy syndrome	0.0149	0.0441	CbGbCtD
Sirolimus—CYP3A7—Carbamazepine—epilepsy syndrome	0.0149	0.0441	CbGbCtD
Sirolimus—CYP3A7—Phenytoin—epilepsy syndrome	0.0134	0.0395	CbGbCtD
Sirolimus—CYP3A7-CYP3A51P—Phenytoin—epilepsy syndrome	0.0134	0.0395	CbGbCtD
Sirolimus—ABCB1—Levetiracetam—epilepsy syndrome	0.0127	0.0375	CbGbCtD
Sirolimus—CYP3A7-CYP3A51P—Phenobarbital—epilepsy syndrome	0.0119	0.0352	CbGbCtD
Sirolimus—CYP3A7—Phenobarbital—epilepsy syndrome	0.0119	0.0352	CbGbCtD
Sirolimus—CYP3A7-CYP3A51P—Midazolam—epilepsy syndrome	0.0117	0.0347	CbGbCtD
Sirolimus—CYP3A7—Midazolam—epilepsy syndrome	0.0117	0.0347	CbGbCtD
Sirolimus—CYP3A7—Diazepam—epilepsy syndrome	0.0113	0.0334	CbGbCtD
Sirolimus—CYP3A7-CYP3A51P—Diazepam—epilepsy syndrome	0.0113	0.0334	CbGbCtD
Sirolimus—CYP3A5—Carbamazepine—epilepsy syndrome	0.0112	0.0331	CbGbCtD
Sirolimus—CYP3A5—Phenytoin—epilepsy syndrome	0.01	0.0297	CbGbCtD
Sirolimus—CYP3A5—Phenobarbital—epilepsy syndrome	0.00893	0.0264	CbGbCtD
Sirolimus—CYP3A5—Midazolam—epilepsy syndrome	0.00881	0.0261	CbGbCtD
Sirolimus—ABCB1—Clobazam—epilepsy syndrome	0.00877	0.026	CbGbCtD
Sirolimus—CYP3A5—Diazepam—epilepsy syndrome	0.00847	0.0251	CbGbCtD
Sirolimus—ABCB1—Lamotrigine—epilepsy syndrome	0.00845	0.025	CbGbCtD
Sirolimus—ABCB1—Carbamazepine—epilepsy syndrome	0.00727	0.0215	CbGbCtD
Sirolimus—CYP3A4—Oxcarbazepine—epilepsy syndrome	0.00694	0.0205	CbGbCtD
Sirolimus—CYP3A5—Valproic Acid—epilepsy syndrome	0.00667	0.0197	CbGbCtD
Sirolimus—ABCB1—Phenytoin—epilepsy syndrome	0.00652	0.0193	CbGbCtD
Sirolimus—CYP3A4—Felbamate—epilepsy syndrome	0.00645	0.0191	CbGbCtD
Sirolimus—CYP3A4—Trimethadione—epilepsy syndrome	0.00645	0.0191	CbGbCtD
Sirolimus—CYP3A4—Fosphenytoin—epilepsy syndrome	0.00606	0.0179	CbGbCtD
Sirolimus—ABCB1—Phenobarbital—epilepsy syndrome	0.00581	0.0172	CbGbCtD
Sirolimus—ABCB1—Midazolam—epilepsy syndrome	0.00573	0.017	CbGbCtD
Sirolimus—ABCB1—Diazepam—epilepsy syndrome	0.00551	0.0163	CbGbCtD
Sirolimus—CYP3A4—Clonazepam—epilepsy syndrome	0.00548	0.0162	CbGbCtD
Sirolimus—CYP3A4—Clobazam—epilepsy syndrome	0.00526	0.0156	CbGbCtD
Sirolimus—CYP3A4—Rufinamide—epilepsy syndrome	0.00447	0.0132	CbGbCtD
Sirolimus—CYP3A4—Carbamazepine—epilepsy syndrome	0.00436	0.0129	CbGbCtD
Sirolimus—CYP3A4—Primidone—epilepsy syndrome	0.00407	0.012	CbGbCtD
Sirolimus—CYP3A4—Phenytoin—epilepsy syndrome	0.00391	0.0116	CbGbCtD
Sirolimus—CYP3A4—Propofol—epilepsy syndrome	0.00364	0.0108	CbGbCtD
Sirolimus—CYP3A4—Acetazolamide—epilepsy syndrome	0.00348	0.0103	CbGbCtD
Sirolimus—CYP3A4—Phenobarbital—epilepsy syndrome	0.00348	0.0103	CbGbCtD
Sirolimus—CYP3A4—Midazolam—epilepsy syndrome	0.00343	0.0102	CbGbCtD
Sirolimus—CYP3A4—Diazepam—epilepsy syndrome	0.0033	0.00977	CbGbCtD
Sirolimus—CYP3A4—Zonisamide—epilepsy syndrome	0.00322	0.00954	CbGbCtD
Sirolimus—MTOR—forelimb—epilepsy syndrome	0.00316	0.11	CbGeAlD
Sirolimus—CYP3A4—Valproic Acid—epilepsy syndrome	0.0026	0.0077	CbGbCtD
Sirolimus—CYP3A4—Topiramate—epilepsy syndrome	0.00235	0.00695	CbGbCtD
Sirolimus—EIF4E—forebrain—epilepsy syndrome	0.00185	0.0645	CbGeAlD
Sirolimus—EIF4E—telencephalon—epilepsy syndrome	0.0017	0.0593	CbGeAlD
Sirolimus—MTOR—hindbrain—epilepsy syndrome	0.0013	0.0451	CbGeAlD
Sirolimus—EIF4E—head—epilepsy syndrome	0.00106	0.0369	CbGeAlD
Sirolimus—EIF4E—nervous system—epilepsy syndrome	0.00101	0.035	CbGeAlD
Sirolimus—SLC47A1—hindbrain—epilepsy syndrome	0.001	0.0349	CbGeAlD
Sirolimus—EIF4E—central nervous system—epilepsy syndrome	0.000969	0.0337	CbGeAlD
Sirolimus—Pimecrolimus—MTOR—epilepsy syndrome	0.000882	0.266	CrCbGaD
Sirolimus—Everolimus—MTOR—epilepsy syndrome	0.000882	0.266	CrCbGaD
Sirolimus—FGF2—medulla oblongata—epilepsy syndrome	0.000817	0.0284	CbGeAlD
Sirolimus—EIF4E—brain—epilepsy syndrome	0.000769	0.0268	CbGeAlD
Sirolimus—FGF2—midbrain—epilepsy syndrome	0.000746	0.026	CbGeAlD
Sirolimus—MTOR—brainstem—epilepsy syndrome	0.000743	0.0259	CbGeAlD
Sirolimus—FGF2—spinal cord—epilepsy syndrome	0.000728	0.0253	CbGeAlD
Sirolimus—MTOR—forebrain—epilepsy syndrome	0.000717	0.025	CbGeAlD
Sirolimus—MTOR—telencephalon—epilepsy syndrome	0.00066	0.023	CbGeAlD
Sirolimus—FKBP1A—forebrain—epilepsy syndrome	0.000645	0.0225	CbGeAlD
Sirolimus—Temsirolimus—MTOR—epilepsy syndrome	0.000596	0.18	CrCbGaD
Sirolimus—FKBP1A—telencephalon—epilepsy syndrome	0.000593	0.0206	CbGeAlD
Sirolimus—FGF2—cerebellum—epilepsy syndrome	0.000577	0.0201	CbGeAlD
Sirolimus—SLC47A1—brainstem—epilepsy syndrome	0.000574	0.02	CbGeAlD
Sirolimus—Tacrolimus—MTOR—epilepsy syndrome	0.000524	0.158	CrCbGaD
Sirolimus—FGF2—brain—epilepsy syndrome	0.000469	0.0163	CbGeAlD
Sirolimus—FKBP1A—medulla oblongata—epilepsy syndrome	0.000466	0.0162	CbGeAlD
Sirolimus—MTOR—spinal cord—epilepsy syndrome	0.000462	0.0161	CbGeAlD
Sirolimus—FKBP1A—midbrain—epilepsy syndrome	0.000426	0.0148	CbGeAlD
Sirolimus—FKBP1A—spinal cord—epilepsy syndrome	0.000416	0.0145	CbGeAlD
Sirolimus—MTOR—head—epilepsy syndrome	0.000411	0.0143	CbGeAlD
Sirolimus—SLC47A1—medulla oblongata—epilepsy syndrome	0.000401	0.0139	CbGeAlD
Sirolimus—MTOR—nervous system—epilepsy syndrome	0.000389	0.0136	CbGeAlD
Sirolimus—MTOR—central nervous system—epilepsy syndrome	0.000375	0.013	CbGeAlD
Sirolimus—FKBP1A—head—epilepsy syndrome	0.000369	0.0129	CbGeAlD
Sirolimus—MTOR—cerebellum—epilepsy syndrome	0.000366	0.0128	CbGeAlD
Sirolimus—SLC47A1—spinal cord—epilepsy syndrome	0.000357	0.0124	CbGeAlD
Sirolimus—FKBP1A—nervous system—epilepsy syndrome	0.00035	0.0122	CbGeAlD
Sirolimus—FKBP1A—central nervous system—epilepsy syndrome	0.000337	0.0117	CbGeAlD
Sirolimus—FKBP1A—cerebellum—epilepsy syndrome	0.00033	0.0115	CbGeAlD
Sirolimus—SLC47A1—head—epilepsy syndrome	0.000317	0.011	CbGeAlD
Sirolimus—SLC47A1—nervous system—epilepsy syndrome	0.000301	0.0105	CbGeAlD
Sirolimus—MTOR—brain—epilepsy syndrome	0.000298	0.0104	CbGeAlD
Sirolimus—SLC47A1—central nervous system—epilepsy syndrome	0.00029	0.0101	CbGeAlD
Sirolimus—SLC47A1—cerebellum—epilepsy syndrome	0.000283	0.00986	CbGeAlD
Sirolimus—FKBP1A—brain—epilepsy syndrome	0.000268	0.00932	CbGeAlD
Sirolimus—SLC47A1—brain—epilepsy syndrome	0.00023	0.00801	CbGeAlD
Sirolimus—ABCB1—forebrain—epilepsy syndrome	0.000149	0.00519	CbGeAlD
Sirolimus—Temsirolimus—CYP2D6—epilepsy syndrome	0.000143	0.0433	CrCbGaD
Sirolimus—ABCB1—telencephalon—epilepsy syndrome	0.000137	0.00478	CbGeAlD
Sirolimus—CYP3A4—nervous system—epilepsy syndrome	0.000114	0.00398	CbGeAlD
Sirolimus—CYP3A4—central nervous system—epilepsy syndrome	0.00011	0.00383	CbGeAlD
Sirolimus—ABCB1—medulla oblongata—epilepsy syndrome	0.000108	0.00375	CbGeAlD
Sirolimus—Temsirolimus—ABCB1—epilepsy syndrome	0.000102	0.0309	CrCbGaD
Sirolimus—ABCB1—midbrain—epilepsy syndrome	9.85e-05	0.00343	CbGeAlD
Sirolimus—ABCB1—spinal cord—epilepsy syndrome	9.61e-05	0.00335	CbGeAlD
Sirolimus—Tacrolimus—ALB—epilepsy syndrome	9.45e-05	0.0285	CrCbGaD
Sirolimus—Tacrolimus—ABCB1—epilepsy syndrome	9.01e-05	0.0272	CrCbGaD
Sirolimus—ABCB1—head—epilepsy syndrome	8.54e-05	0.00297	CbGeAlD
Sirolimus—ABCB1—nervous system—epilepsy syndrome	8.1e-05	0.00282	CbGeAlD
Sirolimus—ABCB1—central nervous system—epilepsy syndrome	7.8e-05	0.00271	CbGeAlD
Sirolimus—ABCB1—cerebellum—epilepsy syndrome	7.62e-05	0.00265	CbGeAlD
Sirolimus—ABCB1—brain—epilepsy syndrome	6.19e-05	0.00215	CbGeAlD
Sirolimus—Dermatitis—Vigabatrin—epilepsy syndrome	2.37e-05	0.000147	CcSEcCtD
Sirolimus—Urethral disorder—Topiramate—epilepsy syndrome	2.37e-05	0.000147	CcSEcCtD
Sirolimus—Pruritus—Oxcarbazepine—epilepsy syndrome	2.37e-05	0.000146	CcSEcCtD
Sirolimus—Hypersensitivity—Carbamazepine—epilepsy syndrome	2.37e-05	0.000146	CcSEcCtD
Sirolimus—Headache—Vigabatrin—epilepsy syndrome	2.36e-05	0.000146	CcSEcCtD
Sirolimus—Hypertension—Pregabalin—epilepsy syndrome	2.36e-05	0.000146	CcSEcCtD
Sirolimus—Vomiting—Diazepam—epilepsy syndrome	2.36e-05	0.000146	CcSEcCtD
Sirolimus—Anorexia—Valproic Acid—epilepsy syndrome	2.35e-05	0.000145	CcSEcCtD
Sirolimus—Tremor—Gabapentin—epilepsy syndrome	2.35e-05	0.000145	CcSEcCtD
Sirolimus—Rash—Diazepam—epilepsy syndrome	2.34e-05	0.000145	CcSEcCtD
Sirolimus—Dermatitis—Diazepam—epilepsy syndrome	2.34e-05	0.000144	CcSEcCtD
Sirolimus—Visual impairment—Topiramate—epilepsy syndrome	2.33e-05	0.000144	CcSEcCtD
Sirolimus—Myalgia—Pregabalin—epilepsy syndrome	2.33e-05	0.000144	CcSEcCtD
Sirolimus—Chest pain—Pregabalin—epilepsy syndrome	2.33e-05	0.000144	CcSEcCtD
Sirolimus—Arthralgia—Pregabalin—epilepsy syndrome	2.33e-05	0.000144	CcSEcCtD
Sirolimus—Ill-defined disorder—Gabapentin—epilepsy syndrome	2.33e-05	0.000144	CcSEcCtD
Sirolimus—Dizziness—Zonisamide—epilepsy syndrome	2.32e-05	0.000144	CcSEcCtD
Sirolimus—Headache—Diazepam—epilepsy syndrome	2.32e-05	0.000144	CcSEcCtD
Sirolimus—Anxiety—Pregabalin—epilepsy syndrome	2.32e-05	0.000143	CcSEcCtD
Sirolimus—Diarrhoea—Clonazepam—epilepsy syndrome	2.32e-05	0.000143	CcSEcCtD
Sirolimus—Anaemia—Gabapentin—epilepsy syndrome	2.32e-05	0.000143	CcSEcCtD
Sirolimus—Unspecified disorder of skin and subcutaneous tissue—Pregabalin—epilepsy syndrome	2.31e-05	0.000143	CcSEcCtD
Sirolimus—Hypotension—Valproic Acid—epilepsy syndrome	2.31e-05	0.000142	CcSEcCtD
Sirolimus—Asthenia—Carbamazepine—epilepsy syndrome	2.31e-05	0.000142	CcSEcCtD
Sirolimus—Agitation—Gabapentin—epilepsy syndrome	2.3e-05	0.000142	CcSEcCtD
Sirolimus—Diarrhoea—Phenytoin—epilepsy syndrome	2.3e-05	0.000142	CcSEcCtD
Sirolimus—Discomfort—Pregabalin—epilepsy syndrome	2.3e-05	0.000142	CcSEcCtD
Sirolimus—Nausea—Fosphenytoin—epilepsy syndrome	2.3e-05	0.000142	CcSEcCtD
Sirolimus—Diarrhoea—Oxcarbazepine—epilepsy syndrome	2.29e-05	0.000141	CcSEcCtD
Sirolimus—Angioedema—Gabapentin—epilepsy syndrome	2.29e-05	0.000141	CcSEcCtD
Sirolimus—Hypersensitivity—Lamotrigine—epilepsy syndrome	2.29e-05	0.000141	CcSEcCtD
Sirolimus—Vomiting—Felbamate—epilepsy syndrome	2.28e-05	0.000141	CcSEcCtD
Sirolimus—Pruritus—Carbamazepine—epilepsy syndrome	2.27e-05	0.00014	CcSEcCtD
Sirolimus—Rash—Felbamate—epilepsy syndrome	2.26e-05	0.00014	CcSEcCtD
Sirolimus—Dermatitis—Felbamate—epilepsy syndrome	2.26e-05	0.00014	CcSEcCtD
Sirolimus—Malaise—Gabapentin—epilepsy syndrome	2.26e-05	0.00014	CcSEcCtD
Sirolimus—Tinnitus—Topiramate—epilepsy syndrome	2.26e-05	0.000139	CcSEcCtD
Sirolimus—Headache—Felbamate—epilepsy syndrome	2.25e-05	0.000139	CcSEcCtD
Sirolimus—Confusional state—Pregabalin—epilepsy syndrome	2.25e-05	0.000139	CcSEcCtD
Sirolimus—Musculoskeletal discomfort—Valproic Acid—epilepsy syndrome	2.25e-05	0.000139	CcSEcCtD
Sirolimus—Cardiac disorder—Topiramate—epilepsy syndrome	2.25e-05	0.000139	CcSEcCtD
Sirolimus—Syncope—Gabapentin—epilepsy syndrome	2.25e-05	0.000139	CcSEcCtD
Sirolimus—Leukopenia—Gabapentin—epilepsy syndrome	2.24e-05	0.000139	CcSEcCtD
Sirolimus—Dizziness—Clonazepam—epilepsy syndrome	2.24e-05	0.000138	CcSEcCtD
Sirolimus—Nausea—Vigabatrin—epilepsy syndrome	2.24e-05	0.000138	CcSEcCtD
Sirolimus—Vomiting—Zonisamide—epilepsy syndrome	2.24e-05	0.000138	CcSEcCtD
Sirolimus—Insomnia—Valproic Acid—epilepsy syndrome	2.23e-05	0.000138	CcSEcCtD
Sirolimus—Anaphylactic shock—Pregabalin—epilepsy syndrome	2.23e-05	0.000138	CcSEcCtD
Sirolimus—Oedema—Pregabalin—epilepsy syndrome	2.23e-05	0.000138	CcSEcCtD
Sirolimus—Asthenia—Lamotrigine—epilepsy syndrome	2.23e-05	0.000138	CcSEcCtD
Sirolimus—Dizziness—Phenytoin—epilepsy syndrome	2.23e-05	0.000137	CcSEcCtD
Sirolimus—Rash—Zonisamide—epilepsy syndrome	2.22e-05	0.000137	CcSEcCtD
Sirolimus—Infection—Pregabalin—epilepsy syndrome	2.22e-05	0.000137	CcSEcCtD
Sirolimus—Paraesthesia—Valproic Acid—epilepsy syndrome	2.22e-05	0.000137	CcSEcCtD
Sirolimus—Palpitations—Gabapentin—epilepsy syndrome	2.21e-05	0.000137	CcSEcCtD
Sirolimus—Dermatitis—Zonisamide—epilepsy syndrome	2.21e-05	0.000137	CcSEcCtD
Sirolimus—Dizziness—Oxcarbazepine—epilepsy syndrome	2.21e-05	0.000137	CcSEcCtD
Sirolimus—Nausea—Diazepam—epilepsy syndrome	2.2e-05	0.000136	CcSEcCtD
Sirolimus—Loss of consciousness—Gabapentin—epilepsy syndrome	2.2e-05	0.000136	CcSEcCtD
Sirolimus—Headache—Zonisamide—epilepsy syndrome	2.2e-05	0.000136	CcSEcCtD
Sirolimus—Dyspnoea—Valproic Acid—epilepsy syndrome	2.2e-05	0.000136	CcSEcCtD
Sirolimus—Diarrhoea—Carbamazepine—epilepsy syndrome	2.2e-05	0.000136	CcSEcCtD
Sirolimus—Angiopathy—Topiramate—epilepsy syndrome	2.2e-05	0.000136	CcSEcCtD
Sirolimus—Pruritus—Lamotrigine—epilepsy syndrome	2.2e-05	0.000136	CcSEcCtD
Sirolimus—Shock—Pregabalin—epilepsy syndrome	2.19e-05	0.000136	CcSEcCtD
Sirolimus—Somnolence—Valproic Acid—epilepsy syndrome	2.19e-05	0.000135	CcSEcCtD
Sirolimus—Immune system disorder—Topiramate—epilepsy syndrome	2.19e-05	0.000135	CcSEcCtD
Sirolimus—Nervous system disorder—Pregabalin—epilepsy syndrome	2.19e-05	0.000135	CcSEcCtD
Sirolimus—Cough—Gabapentin—epilepsy syndrome	2.19e-05	0.000135	CcSEcCtD
Sirolimus—Thrombocytopenia—Pregabalin—epilepsy syndrome	2.18e-05	0.000135	CcSEcCtD
Sirolimus—Mediastinal disorder—Topiramate—epilepsy syndrome	2.18e-05	0.000135	CcSEcCtD
Sirolimus—Tachycardia—Pregabalin—epilepsy syndrome	2.18e-05	0.000134	CcSEcCtD
Sirolimus—Chills—Topiramate—epilepsy syndrome	2.17e-05	0.000134	CcSEcCtD
Sirolimus—Dyspepsia—Valproic Acid—epilepsy syndrome	2.17e-05	0.000134	CcSEcCtD
Sirolimus—Skin disorder—Pregabalin—epilepsy syndrome	2.17e-05	0.000134	CcSEcCtD
Sirolimus—Hypertension—Gabapentin—epilepsy syndrome	2.16e-05	0.000134	CcSEcCtD
Sirolimus—Hyperhidrosis—Pregabalin—epilepsy syndrome	2.16e-05	0.000133	CcSEcCtD
Sirolimus—Vomiting—Clonazepam—epilepsy syndrome	2.15e-05	0.000133	CcSEcCtD
Sirolimus—Decreased appetite—Valproic Acid—epilepsy syndrome	2.14e-05	0.000132	CcSEcCtD
Sirolimus—Vomiting—Phenytoin—epilepsy syndrome	2.14e-05	0.000132	CcSEcCtD
Sirolimus—Rash—Clonazepam—epilepsy syndrome	2.14e-05	0.000132	CcSEcCtD
Sirolimus—Dermatitis—Clonazepam—epilepsy syndrome	2.13e-05	0.000132	CcSEcCtD
Sirolimus—Chest pain—Gabapentin—epilepsy syndrome	2.13e-05	0.000132	CcSEcCtD
Sirolimus—Arthralgia—Gabapentin—epilepsy syndrome	2.13e-05	0.000132	CcSEcCtD
Sirolimus—Myalgia—Gabapentin—epilepsy syndrome	2.13e-05	0.000132	CcSEcCtD
Sirolimus—Nausea—Felbamate—epilepsy syndrome	2.13e-05	0.000132	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Valproic Acid—epilepsy syndrome	2.13e-05	0.000132	CcSEcCtD
Sirolimus—Vomiting—Oxcarbazepine—epilepsy syndrome	2.13e-05	0.000131	CcSEcCtD
Sirolimus—Anxiety—Gabapentin—epilepsy syndrome	2.13e-05	0.000131	CcSEcCtD
Sirolimus—Anorexia—Pregabalin—epilepsy syndrome	2.13e-05	0.000131	CcSEcCtD
Sirolimus—Dizziness—Carbamazepine—epilepsy syndrome	2.12e-05	0.000131	CcSEcCtD
Sirolimus—Diarrhoea—Lamotrigine—epilepsy syndrome	2.12e-05	0.000131	CcSEcCtD
Sirolimus—Headache—Clonazepam—epilepsy syndrome	2.12e-05	0.000131	CcSEcCtD
Sirolimus—Rash—Phenytoin—epilepsy syndrome	2.12e-05	0.000131	CcSEcCtD
Sirolimus—Dermatitis—Phenytoin—epilepsy syndrome	2.12e-05	0.000131	CcSEcCtD
Sirolimus—Unspecified disorder of skin and subcutaneous tissue—Gabapentin—epilepsy syndrome	2.12e-05	0.000131	CcSEcCtD
Sirolimus—Rash—Oxcarbazepine—epilepsy syndrome	2.11e-05	0.00013	CcSEcCtD
Sirolimus—Constipation—Valproic Acid—epilepsy syndrome	2.11e-05	0.00013	CcSEcCtD
Sirolimus—Pain—Valproic Acid—epilepsy syndrome	2.11e-05	0.00013	CcSEcCtD
Sirolimus—Dermatitis—Oxcarbazepine—epilepsy syndrome	2.11e-05	0.00013	CcSEcCtD
Sirolimus—Headache—Phenytoin—epilepsy syndrome	2.11e-05	0.00013	CcSEcCtD
Sirolimus—Malnutrition—Topiramate—epilepsy syndrome	2.11e-05	0.00013	CcSEcCtD
Sirolimus—Discomfort—Gabapentin—epilepsy syndrome	2.11e-05	0.00013	CcSEcCtD
Sirolimus—Headache—Oxcarbazepine—epilepsy syndrome	2.1e-05	0.00013	CcSEcCtD
Sirolimus—Nausea—Zonisamide—epilepsy syndrome	2.09e-05	0.000129	CcSEcCtD
Sirolimus—Hypotension—Pregabalin—epilepsy syndrome	2.08e-05	0.000129	CcSEcCtD
Sirolimus—Flatulence—Topiramate—epilepsy syndrome	2.08e-05	0.000128	CcSEcCtD
Sirolimus—Tension—Topiramate—epilepsy syndrome	2.07e-05	0.000128	CcSEcCtD
Sirolimus—Confusional state—Gabapentin—epilepsy syndrome	2.06e-05	0.000127	CcSEcCtD
Sirolimus—Dizziness—Lamotrigine—epilepsy syndrome	2.05e-05	0.000127	CcSEcCtD
Sirolimus—Nervousness—Topiramate—epilepsy syndrome	2.05e-05	0.000126	CcSEcCtD
Sirolimus—Oedema—Gabapentin—epilepsy syndrome	2.05e-05	0.000126	CcSEcCtD
Sirolimus—Anaphylactic shock—Gabapentin—epilepsy syndrome	2.05e-05	0.000126	CcSEcCtD
Sirolimus—Vomiting—Carbamazepine—epilepsy syndrome	2.04e-05	0.000126	CcSEcCtD
Sirolimus—Back pain—Topiramate—epilepsy syndrome	2.04e-05	0.000126	CcSEcCtD
Sirolimus—Feeling abnormal—Valproic Acid—epilepsy syndrome	2.03e-05	0.000126	CcSEcCtD
Sirolimus—Musculoskeletal discomfort—Pregabalin—epilepsy syndrome	2.03e-05	0.000126	CcSEcCtD
Sirolimus—Infection—Gabapentin—epilepsy syndrome	2.03e-05	0.000126	CcSEcCtD
Sirolimus—Muscle spasms—Topiramate—epilepsy syndrome	2.03e-05	0.000125	CcSEcCtD
Sirolimus—Rash—Carbamazepine—epilepsy syndrome	2.03e-05	0.000125	CcSEcCtD
Sirolimus—Dermatitis—Carbamazepine—epilepsy syndrome	2.02e-05	0.000125	CcSEcCtD
Sirolimus—Gastrointestinal pain—Valproic Acid—epilepsy syndrome	2.02e-05	0.000125	CcSEcCtD
Sirolimus—Insomnia—Pregabalin—epilepsy syndrome	2.02e-05	0.000125	CcSEcCtD
Sirolimus—Nausea—Clonazepam—epilepsy syndrome	2.01e-05	0.000124	CcSEcCtD
Sirolimus—Headache—Carbamazepine—epilepsy syndrome	2.01e-05	0.000124	CcSEcCtD
Sirolimus—Shock—Gabapentin—epilepsy syndrome	2.01e-05	0.000124	CcSEcCtD
Sirolimus—Nervous system disorder—Gabapentin—epilepsy syndrome	2.01e-05	0.000124	CcSEcCtD
Sirolimus—Paraesthesia—Pregabalin—epilepsy syndrome	2e-05	0.000124	CcSEcCtD
Sirolimus—Thrombocytopenia—Gabapentin—epilepsy syndrome	2e-05	0.000124	CcSEcCtD
Sirolimus—Nausea—Phenytoin—epilepsy syndrome	2e-05	0.000123	CcSEcCtD
Sirolimus—Tachycardia—Gabapentin—epilepsy syndrome	2e-05	0.000123	CcSEcCtD
Sirolimus—Dyspnoea—Pregabalin—epilepsy syndrome	1.99e-05	0.000123	CcSEcCtD
Sirolimus—Nausea—Oxcarbazepine—epilepsy syndrome	1.99e-05	0.000123	CcSEcCtD
Sirolimus—Skin disorder—Gabapentin—epilepsy syndrome	1.99e-05	0.000123	CcSEcCtD
Sirolimus—Somnolence—Pregabalin—epilepsy syndrome	1.98e-05	0.000122	CcSEcCtD
Sirolimus—Hyperhidrosis—Gabapentin—epilepsy syndrome	1.98e-05	0.000122	CcSEcCtD
Sirolimus—Tremor—Topiramate—epilepsy syndrome	1.98e-05	0.000122	CcSEcCtD
Sirolimus—Vomiting—Lamotrigine—epilepsy syndrome	1.97e-05	0.000122	CcSEcCtD
Sirolimus—Rash—Lamotrigine—epilepsy syndrome	1.96e-05	0.000121	CcSEcCtD
Sirolimus—Ill-defined disorder—Topiramate—epilepsy syndrome	1.96e-05	0.000121	CcSEcCtD
Sirolimus—Dermatitis—Lamotrigine—epilepsy syndrome	1.96e-05	0.000121	CcSEcCtD
Sirolimus—Abdominal pain—Valproic Acid—epilepsy syndrome	1.95e-05	0.00012	CcSEcCtD
Sirolimus—Body temperature increased—Valproic Acid—epilepsy syndrome	1.95e-05	0.00012	CcSEcCtD
Sirolimus—Anorexia—Gabapentin—epilepsy syndrome	1.95e-05	0.00012	CcSEcCtD
Sirolimus—Anaemia—Topiramate—epilepsy syndrome	1.95e-05	0.00012	CcSEcCtD
Sirolimus—Headache—Lamotrigine—epilepsy syndrome	1.95e-05	0.00012	CcSEcCtD
Sirolimus—Decreased appetite—Pregabalin—epilepsy syndrome	1.94e-05	0.00012	CcSEcCtD
Sirolimus—Agitation—Topiramate—epilepsy syndrome	1.94e-05	0.00012	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Pregabalin—epilepsy syndrome	1.93e-05	0.000119	CcSEcCtD
Sirolimus—Hypotension—Gabapentin—epilepsy syndrome	1.91e-05	0.000118	CcSEcCtD
Sirolimus—Nausea—Carbamazepine—epilepsy syndrome	1.91e-05	0.000118	CcSEcCtD
Sirolimus—Pain—Pregabalin—epilepsy syndrome	1.91e-05	0.000118	CcSEcCtD
Sirolimus—Constipation—Pregabalin—epilepsy syndrome	1.91e-05	0.000118	CcSEcCtD
Sirolimus—Malaise—Topiramate—epilepsy syndrome	1.9e-05	0.000117	CcSEcCtD
Sirolimus—Syncope—Topiramate—epilepsy syndrome	1.89e-05	0.000117	CcSEcCtD
Sirolimus—Leukopenia—Topiramate—epilepsy syndrome	1.89e-05	0.000117	CcSEcCtD
Sirolimus—Musculoskeletal discomfort—Gabapentin—epilepsy syndrome	1.86e-05	0.000115	CcSEcCtD
Sirolimus—Palpitations—Topiramate—epilepsy syndrome	1.86e-05	0.000115	CcSEcCtD
Sirolimus—Loss of consciousness—Topiramate—epilepsy syndrome	1.85e-05	0.000114	CcSEcCtD
Sirolimus—Insomnia—Gabapentin—epilepsy syndrome	1.85e-05	0.000114	CcSEcCtD
Sirolimus—Nausea—Lamotrigine—epilepsy syndrome	1.84e-05	0.000114	CcSEcCtD
Sirolimus—Cough—Topiramate—epilepsy syndrome	1.84e-05	0.000114	CcSEcCtD
Sirolimus—Feeling abnormal—Pregabalin—epilepsy syndrome	1.84e-05	0.000114	CcSEcCtD
Sirolimus—Paraesthesia—Gabapentin—epilepsy syndrome	1.84e-05	0.000113	CcSEcCtD
Sirolimus—Gastrointestinal pain—Pregabalin—epilepsy syndrome	1.82e-05	0.000113	CcSEcCtD
Sirolimus—Dyspnoea—Gabapentin—epilepsy syndrome	1.82e-05	0.000113	CcSEcCtD
Sirolimus—Hypertension—Topiramate—epilepsy syndrome	1.82e-05	0.000112	CcSEcCtD
Sirolimus—Somnolence—Gabapentin—epilepsy syndrome	1.82e-05	0.000112	CcSEcCtD
Sirolimus—Hypersensitivity—Valproic Acid—epilepsy syndrome	1.82e-05	0.000112	CcSEcCtD
Sirolimus—Dyspepsia—Gabapentin—epilepsy syndrome	1.8e-05	0.000111	CcSEcCtD
Sirolimus—Chest pain—Topiramate—epilepsy syndrome	1.8e-05	0.000111	CcSEcCtD
Sirolimus—Arthralgia—Topiramate—epilepsy syndrome	1.8e-05	0.000111	CcSEcCtD
Sirolimus—Myalgia—Topiramate—epilepsy syndrome	1.8e-05	0.000111	CcSEcCtD
Sirolimus—Anxiety—Topiramate—epilepsy syndrome	1.79e-05	0.00011	CcSEcCtD
Sirolimus—Unspecified disorder of skin and subcutaneous tissue—Topiramate—epilepsy syndrome	1.78e-05	0.00011	CcSEcCtD
Sirolimus—Decreased appetite—Gabapentin—epilepsy syndrome	1.78e-05	0.00011	CcSEcCtD
Sirolimus—Discomfort—Topiramate—epilepsy syndrome	1.77e-05	0.00011	CcSEcCtD
Sirolimus—Asthenia—Valproic Acid—epilepsy syndrome	1.77e-05	0.000109	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Gabapentin—epilepsy syndrome	1.77e-05	0.000109	CcSEcCtD
Sirolimus—Abdominal pain—Pregabalin—epilepsy syndrome	1.76e-05	0.000109	CcSEcCtD
Sirolimus—Body temperature increased—Pregabalin—epilepsy syndrome	1.76e-05	0.000109	CcSEcCtD
Sirolimus—Pain—Gabapentin—epilepsy syndrome	1.75e-05	0.000108	CcSEcCtD
Sirolimus—Constipation—Gabapentin—epilepsy syndrome	1.75e-05	0.000108	CcSEcCtD
Sirolimus—Pruritus—Valproic Acid—epilepsy syndrome	1.75e-05	0.000108	CcSEcCtD
Sirolimus—Confusional state—Topiramate—epilepsy syndrome	1.74e-05	0.000107	CcSEcCtD
Sirolimus—Oedema—Topiramate—epilepsy syndrome	1.72e-05	0.000106	CcSEcCtD
Sirolimus—Infection—Topiramate—epilepsy syndrome	1.71e-05	0.000106	CcSEcCtD
Sirolimus—Shock—Topiramate—epilepsy syndrome	1.69e-05	0.000105	CcSEcCtD
Sirolimus—Diarrhoea—Valproic Acid—epilepsy syndrome	1.69e-05	0.000104	CcSEcCtD
Sirolimus—Nervous system disorder—Topiramate—epilepsy syndrome	1.69e-05	0.000104	CcSEcCtD
Sirolimus—Feeling abnormal—Gabapentin—epilepsy syndrome	1.69e-05	0.000104	CcSEcCtD
Sirolimus—Thrombocytopenia—Topiramate—epilepsy syndrome	1.68e-05	0.000104	CcSEcCtD
Sirolimus—Tachycardia—Topiramate—epilepsy syndrome	1.68e-05	0.000104	CcSEcCtD
Sirolimus—Gastrointestinal pain—Gabapentin—epilepsy syndrome	1.67e-05	0.000103	CcSEcCtD
Sirolimus—Skin disorder—Topiramate—epilepsy syndrome	1.67e-05	0.000103	CcSEcCtD
Sirolimus—Hyperhidrosis—Topiramate—epilepsy syndrome	1.66e-05	0.000103	CcSEcCtD
Sirolimus—Hypersensitivity—Pregabalin—epilepsy syndrome	1.64e-05	0.000102	CcSEcCtD
Sirolimus—Anorexia—Topiramate—epilepsy syndrome	1.64e-05	0.000101	CcSEcCtD
Sirolimus—Dizziness—Valproic Acid—epilepsy syndrome	1.63e-05	0.000101	CcSEcCtD
Sirolimus—Abdominal pain—Gabapentin—epilepsy syndrome	1.62e-05	9.99e-05	CcSEcCtD
Sirolimus—Body temperature increased—Gabapentin—epilepsy syndrome	1.62e-05	9.99e-05	CcSEcCtD
Sirolimus—Hypotension—Topiramate—epilepsy syndrome	1.61e-05	9.93e-05	CcSEcCtD
Sirolimus—Asthenia—Pregabalin—epilepsy syndrome	1.6e-05	9.88e-05	CcSEcCtD
Sirolimus—Pruritus—Pregabalin—epilepsy syndrome	1.58e-05	9.75e-05	CcSEcCtD
Sirolimus—Vomiting—Valproic Acid—epilepsy syndrome	1.57e-05	9.69e-05	CcSEcCtD
Sirolimus—Musculoskeletal discomfort—Topiramate—epilepsy syndrome	1.57e-05	9.68e-05	CcSEcCtD
Sirolimus—Insomnia—Topiramate—epilepsy syndrome	1.56e-05	9.61e-05	CcSEcCtD
Sirolimus—Rash—Valproic Acid—epilepsy syndrome	1.56e-05	9.61e-05	CcSEcCtD
Sirolimus—Dermatitis—Valproic Acid—epilepsy syndrome	1.55e-05	9.6e-05	CcSEcCtD
Sirolimus—Headache—Valproic Acid—epilepsy syndrome	1.55e-05	9.55e-05	CcSEcCtD
Sirolimus—Paraesthesia—Topiramate—epilepsy syndrome	1.55e-05	9.54e-05	CcSEcCtD
Sirolimus—Dyspnoea—Topiramate—epilepsy syndrome	1.53e-05	9.48e-05	CcSEcCtD
Sirolimus—Somnolence—Topiramate—epilepsy syndrome	1.53e-05	9.45e-05	CcSEcCtD
Sirolimus—Diarrhoea—Pregabalin—epilepsy syndrome	1.53e-05	9.43e-05	CcSEcCtD
Sirolimus—Dyspepsia—Topiramate—epilepsy syndrome	1.51e-05	9.36e-05	CcSEcCtD
Sirolimus—Hypersensitivity—Gabapentin—epilepsy syndrome	1.51e-05	9.31e-05	CcSEcCtD
Sirolimus—Decreased appetite—Topiramate—epilepsy syndrome	1.5e-05	9.24e-05	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Topiramate—epilepsy syndrome	1.49e-05	9.18e-05	CcSEcCtD
Sirolimus—Dizziness—Pregabalin—epilepsy syndrome	1.48e-05	9.11e-05	CcSEcCtD
Sirolimus—Pain—Topiramate—epilepsy syndrome	1.47e-05	9.09e-05	CcSEcCtD
Sirolimus—Constipation—Topiramate—epilepsy syndrome	1.47e-05	9.09e-05	CcSEcCtD
Sirolimus—Asthenia—Gabapentin—epilepsy syndrome	1.47e-05	9.06e-05	CcSEcCtD
Sirolimus—Nausea—Valproic Acid—epilepsy syndrome	1.47e-05	9.05e-05	CcSEcCtD
Sirolimus—Pruritus—Gabapentin—epilepsy syndrome	1.45e-05	8.94e-05	CcSEcCtD
Sirolimus—Vomiting—Pregabalin—epilepsy syndrome	1.42e-05	8.76e-05	CcSEcCtD
Sirolimus—Feeling abnormal—Topiramate—epilepsy syndrome	1.42e-05	8.76e-05	CcSEcCtD
Sirolimus—Gastrointestinal pain—Topiramate—epilepsy syndrome	1.41e-05	8.69e-05	CcSEcCtD
Sirolimus—Rash—Pregabalin—epilepsy syndrome	1.41e-05	8.69e-05	CcSEcCtD
Sirolimus—Dermatitis—Pregabalin—epilepsy syndrome	1.41e-05	8.68e-05	CcSEcCtD
Sirolimus—Diarrhoea—Gabapentin—epilepsy syndrome	1.4e-05	8.64e-05	CcSEcCtD
Sirolimus—Headache—Pregabalin—epilepsy syndrome	1.4e-05	8.63e-05	CcSEcCtD
Sirolimus—Abdominal pain—Topiramate—epilepsy syndrome	1.36e-05	8.4e-05	CcSEcCtD
Sirolimus—Body temperature increased—Topiramate—epilepsy syndrome	1.36e-05	8.4e-05	CcSEcCtD
Sirolimus—Dizziness—Gabapentin—epilepsy syndrome	1.35e-05	8.35e-05	CcSEcCtD
Sirolimus—Nausea—Pregabalin—epilepsy syndrome	1.32e-05	8.18e-05	CcSEcCtD
Sirolimus—Vomiting—Gabapentin—epilepsy syndrome	1.3e-05	8.03e-05	CcSEcCtD
Sirolimus—Rash—Gabapentin—epilepsy syndrome	1.29e-05	7.97e-05	CcSEcCtD
Sirolimus—Dermatitis—Gabapentin—epilepsy syndrome	1.29e-05	7.96e-05	CcSEcCtD
Sirolimus—Headache—Gabapentin—epilepsy syndrome	1.28e-05	7.91e-05	CcSEcCtD
Sirolimus—Hypersensitivity—Topiramate—epilepsy syndrome	1.27e-05	7.83e-05	CcSEcCtD
Sirolimus—Asthenia—Topiramate—epilepsy syndrome	1.23e-05	7.63e-05	CcSEcCtD
Sirolimus—Pruritus—Topiramate—epilepsy syndrome	1.22e-05	7.52e-05	CcSEcCtD
Sirolimus—Nausea—Gabapentin—epilepsy syndrome	1.21e-05	7.5e-05	CcSEcCtD
Sirolimus—Diarrhoea—Topiramate—epilepsy syndrome	1.18e-05	7.27e-05	CcSEcCtD
Sirolimus—Dizziness—Topiramate—epilepsy syndrome	1.14e-05	7.03e-05	CcSEcCtD
Sirolimus—Vomiting—Topiramate—epilepsy syndrome	1.09e-05	6.76e-05	CcSEcCtD
Sirolimus—Rash—Topiramate—epilepsy syndrome	1.09e-05	6.7e-05	CcSEcCtD
Sirolimus—Dermatitis—Topiramate—epilepsy syndrome	1.08e-05	6.7e-05	CcSEcCtD
Sirolimus—Headache—Topiramate—epilepsy syndrome	1.08e-05	6.66e-05	CcSEcCtD
Sirolimus—Nausea—Topiramate—epilepsy syndrome	1.02e-05	6.31e-05	CcSEcCtD
Sirolimus—SLCO1B1—Metabolism—SLC2A1—epilepsy syndrome	4.11e-06	4.78e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—PLCB1—epilepsy syndrome	4.06e-06	4.73e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—TH—epilepsy syndrome	4.05e-06	4.71e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CXCL12—epilepsy syndrome	4.04e-06	4.7e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—BDKRB2—epilepsy syndrome	4.04e-06	4.7e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling by NGF—AKT1—epilepsy syndrome	4.04e-06	4.7e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—ADSL—epilepsy syndrome	4.04e-06	4.7e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—FYN—epilepsy syndrome	4.04e-06	4.69e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—CA4—epilepsy syndrome	4.03e-06	4.68e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—QDPR—epilepsy syndrome	4.03e-06	4.68e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—H2AFX—epilepsy syndrome	4.02e-06	4.68e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Biological oxidations—POMC—epilepsy syndrome	4.01e-06	4.67e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—MEF2C—epilepsy syndrome	4.01e-06	4.67e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism of lipids and lipoproteins—PTGS2—epilepsy syndrome	3.99e-06	4.64e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—TSC2—epilepsy syndrome	3.98e-06	4.63e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—CRP—epilepsy syndrome	3.98e-06	4.63e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—ADRA2A—epilepsy syndrome	3.97e-06	4.62e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CNR1—epilepsy syndrome	3.97e-06	4.61e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—JUNB—epilepsy syndrome	3.97e-06	4.61e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—GLUL—epilepsy syndrome	3.96e-06	4.6e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—CCR5—epilepsy syndrome	3.95e-06	4.6e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—BCHE—epilepsy syndrome	3.95e-06	4.6e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—PLCB1—epilepsy syndrome	3.95e-06	4.59e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—CACNA1D—epilepsy syndrome	3.89e-06	4.52e-05	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—CASP3—epilepsy syndrome	3.88e-06	4.52e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—YWHAZ—epilepsy syndrome	3.88e-06	4.51e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—HTR7—epilepsy syndrome	3.87e-06	4.5e-05	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—epilepsy syndrome	3.87e-06	4.49e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—POMC—epilepsy syndrome	3.85e-06	4.47e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—NGF—epilepsy syndrome	3.84e-06	4.46e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—BCL2—epilepsy syndrome	3.79e-06	4.4e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—COX3—epilepsy syndrome	3.79e-06	4.4e-05	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—JUN—epilepsy syndrome	3.77e-06	4.39e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—SLC2A1—epilepsy syndrome	3.77e-06	4.38e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—CCL2—epilepsy syndrome	3.77e-06	4.38e-05	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—epilepsy syndrome	3.76e-06	4.38e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—HBEGF—epilepsy syndrome	3.76e-06	4.37e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—CCR5—epilepsy syndrome	3.73e-06	4.34e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—PLCB1—epilepsy syndrome	3.73e-06	4.34e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—TH—epilepsy syndrome	3.72e-06	4.32e-05	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—SRC—epilepsy syndrome	3.71e-06	4.31e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—RELA—epilepsy syndrome	3.7e-06	4.31e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—AKT3—epilepsy syndrome	3.69e-06	4.29e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—TSC2—epilepsy syndrome	3.68e-06	4.27e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—PRKCB—epilepsy syndrome	3.68e-06	4.27e-05	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—MMP9—epilepsy syndrome	3.67e-06	4.27e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—IL6ST—epilepsy syndrome	3.66e-06	4.26e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—HTR2A—epilepsy syndrome	3.65e-06	4.25e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—TXNRD1—epilepsy syndrome	3.64e-06	4.23e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—MTOR—epilepsy syndrome	3.63e-06	4.22e-05	CbGpPWpGaD
Sirolimus—ABCB1—Transmembrane transport of small molecules—HMOX1—epilepsy syndrome	3.61e-06	4.2e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—ADAM10—epilepsy syndrome	3.6e-06	4.19e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—APOE—epilepsy syndrome	3.6e-06	4.18e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—CACNA2D2—epilepsy syndrome	3.59e-06	4.17e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—KCNB1—epilepsy syndrome	3.59e-06	4.17e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—SLCO1A2—epilepsy syndrome	3.59e-06	4.17e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PFKL—epilepsy syndrome	3.59e-06	4.17e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—SLC6A8—epilepsy syndrome	3.59e-06	4.17e-05	CbGpPWpGaD
Sirolimus—ABCB1—Transmembrane transport of small molecules—AVP—epilepsy syndrome	3.58e-06	4.16e-05	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—SRC—epilepsy syndrome	3.56e-06	4.14e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—SRC—epilepsy syndrome	3.55e-06	4.12e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—AQP1—epilepsy syndrome	3.53e-06	4.1e-05	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—AKT1—epilepsy syndrome	3.52e-06	4.09e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—TSC2—epilepsy syndrome	3.47e-06	4.03e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—AGT—epilepsy syndrome	3.47e-06	4.03e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—ABCG2—epilepsy syndrome	3.45e-06	4.01e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—S100B—epilepsy syndrome	3.41e-06	3.96e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—FGF2—epilepsy syndrome	3.4e-06	3.96e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—APOE—epilepsy syndrome	3.4e-06	3.95e-05	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—SRC—epilepsy syndrome	3.38e-06	3.93e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—HMOX1—epilepsy syndrome	3.38e-06	3.93e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—IL6ST—epilepsy syndrome	3.38e-06	3.93e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—SOCS3—epilepsy syndrome	3.37e-06	3.92e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CDC42—epilepsy syndrome	3.36e-06	3.91e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—CYP2C19—epilepsy syndrome	3.36e-06	3.91e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—FOS—epilepsy syndrome	3.35e-06	3.9e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—NOS2—epilepsy syndrome	3.35e-06	3.9e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—MTOR—epilepsy syndrome	3.35e-06	3.9e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—IL1B—epilepsy syndrome	3.35e-06	3.89e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—CYP11A1—epilepsy syndrome	3.34e-06	3.88e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—CAT—epilepsy syndrome	3.33e-06	3.88e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—KDR—epilepsy syndrome	3.33e-06	3.87e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—PTGS2—epilepsy syndrome	3.32e-06	3.86e-05	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—VEGFA—epilepsy syndrome	3.3e-06	3.83e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—NEU1—epilepsy syndrome	3.28e-06	3.82e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—UPB1—epilepsy syndrome	3.28e-06	3.82e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—ATIC—epilepsy syndrome	3.28e-06	3.82e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—CASP8—epilepsy syndrome	3.28e-06	3.81e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—AVP—epilepsy syndrome	3.26e-06	3.79e-05	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—AKT1—epilepsy syndrome	3.25e-06	3.78e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—JUN—epilepsy syndrome	3.24e-06	3.77e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—ABCB1—epilepsy syndrome	3.24e-06	3.77e-05	CbGpPWpGaD
Sirolimus—EIF4E—Gene Expression—AKT1—epilepsy syndrome	3.23e-06	3.76e-05	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—epilepsy syndrome	3.23e-06	3.75e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—PRKCB—epilepsy syndrome	3.2e-06	3.72e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—CHRM3—epilepsy syndrome	3.19e-06	3.71e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—KCNJ11—epilepsy syndrome	3.19e-06	3.71e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—IL6ST—epilepsy syndrome	3.19e-06	3.71e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—HSD17B4—epilepsy syndrome	3.16e-06	3.67e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—RELA—epilepsy syndrome	3.16e-06	3.67e-05	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—AKT1—epilepsy syndrome	3.1e-06	3.61e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—HMOX1—epilepsy syndrome	3.1e-06	3.61e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—MTOR—epilepsy syndrome	3.1e-06	3.6e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—HES1—epilepsy syndrome	3.08e-06	3.58e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—CAT—epilepsy syndrome	3.06e-06	3.56e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—GBE1—epilepsy syndrome	3.05e-06	3.55e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PPP1R3C—epilepsy syndrome	3.05e-06	3.55e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—GPX1—epilepsy syndrome	3.02e-06	3.51e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—CYP2D6—epilepsy syndrome	3.01e-06	3.5e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—FYN—epilepsy syndrome	2.99e-06	3.48e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—H2AFX—epilepsy syndrome	2.98e-06	3.47e-05	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—AKT1—epilepsy syndrome	2.98e-06	3.47e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—MEF2C—epilepsy syndrome	2.98e-06	3.46e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—ABCB1—epilepsy syndrome	2.98e-06	3.46e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—FGF2—epilepsy syndrome	2.96e-06	3.44e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—POMC—epilepsy syndrome	2.92e-06	3.39e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—SRC—epilepsy syndrome	2.91e-06	3.38e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—YWHAZ—epilepsy syndrome	2.88e-06	3.35e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—ASAH1—epilepsy syndrome	2.87e-06	3.34e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—ADRA2A—epilepsy syndrome	2.87e-06	3.34e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—BCHE—epilepsy syndrome	2.86e-06	3.32e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—CCL2—epilepsy syndrome	2.85e-06	3.32e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—CASP3—epilepsy syndrome	2.85e-06	3.31e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—NGF—epilepsy syndrome	2.85e-06	3.31e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—BCL2—epilepsy syndrome	2.81e-06	3.27e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—STXBP1—epilepsy syndrome	2.79e-06	3.25e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CCR5—epilepsy syndrome	2.77e-06	3.22e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—GPX1—epilepsy syndrome	2.77e-06	3.22e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—JUN—epilepsy syndrome	2.77e-06	3.22e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—RELA—epilepsy syndrome	2.75e-06	3.19e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—FGF2—epilepsy syndrome	2.73e-06	3.18e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—SLC2A1—epilepsy syndrome	2.73e-06	3.17e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—NT5E—epilepsy syndrome	2.72e-06	3.16e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—ALAD—epilepsy syndrome	2.72e-06	3.16e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—HTR2A—epilepsy syndrome	2.71e-06	3.15e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—PLCB1—epilepsy syndrome	2.7e-06	3.13e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—MMP9—epilepsy syndrome	2.69e-06	3.13e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—SRC—epilepsy syndrome	2.69e-06	3.12e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—TH—epilepsy syndrome	2.69e-06	3.12e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—AGT—epilepsy syndrome	2.64e-06	3.07e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—ABCG2—epilepsy syndrome	2.6e-06	3.03e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—ALDH7A1—epilepsy syndrome	2.6e-06	3.02e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—CACNA1A—epilepsy syndrome	2.6e-06	3.02e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—APOE—epilepsy syndrome	2.59e-06	3.01e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—TSC2—epilepsy syndrome	2.57e-06	2.99e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—AGT—epilepsy syndrome	2.57e-06	2.99e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—ST3GAL3—epilepsy syndrome	2.54e-06	2.95e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—CYP2C19—epilepsy syndrome	2.54e-06	2.95e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—CYP11A1—epilepsy syndrome	2.52e-06	2.93e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—APOE—epilepsy syndrome	2.52e-06	2.93e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—ADSL—epilepsy syndrome	2.49e-06	2.89e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—IL1B—epilepsy syndrome	2.48e-06	2.89e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—SRC—epilepsy syndrome	2.48e-06	2.89e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—KDR—epilepsy syndrome	2.47e-06	2.87e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—PTGS2—epilepsy syndrome	2.47e-06	2.87e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—GLUL—epilepsy syndrome	2.44e-06	2.84e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—AGT—epilepsy syndrome	2.43e-06	2.82e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—VEGFA—epilepsy syndrome	2.42e-06	2.81e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—JUN—epilepsy syndrome	2.41e-06	2.8e-05	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—epilepsy syndrome	2.4e-06	2.79e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—CACNA1D—epilepsy syndrome	2.39e-06	2.78e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—RELA—epilepsy syndrome	2.39e-06	2.78e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—APOE—epilepsy syndrome	2.38e-06	2.76e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—PRKCB—epilepsy syndrome	2.38e-06	2.76e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—IL6ST—epilepsy syndrome	2.37e-06	2.75e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—MTOR—epilepsy syndrome	2.35e-06	2.73e-05	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—AKT1—epilepsy syndrome	2.3e-06	2.68e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—CYP2D6—epilepsy syndrome	2.27e-06	2.64e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—HMOX1—epilepsy syndrome	2.24e-06	2.61e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—TXNRD1—epilepsy syndrome	2.24e-06	2.6e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—POMC—epilepsy syndrome	2.23e-06	2.59e-05	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—AKT1—epilepsy syndrome	2.21e-06	2.57e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—CAT—epilepsy syndrome	2.21e-06	2.57e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—AKT1—epilepsy syndrome	2.2e-06	2.56e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—AQP1—epilepsy syndrome	2.17e-06	2.53e-05	CbGpPWpGaD
Sirolimus—ABCB1—Transmembrane transport of small molecules—ALB—epilepsy syndrome	2.17e-06	2.52e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—ADRA2A—epilepsy syndrome	2.17e-06	2.52e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—POMC—epilepsy syndrome	2.16e-06	2.52e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—SRC—epilepsy syndrome	2.16e-06	2.51e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—CASP3—epilepsy syndrome	2.16e-06	2.51e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—BCHE—epilepsy syndrome	2.16e-06	2.51e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—ABCB1—epilepsy syndrome	2.15e-06	2.5e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CCL2—epilepsy syndrome	2.12e-06	2.46e-05	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—AKT1—epilepsy syndrome	2.1e-06	2.45e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—JUN—epilepsy syndrome	2.1e-06	2.44e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—SLC2A1—epilepsy syndrome	2.06e-06	2.39e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—POMC—epilepsy syndrome	2.04e-06	2.38e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—MMP9—epilepsy syndrome	2.04e-06	2.37e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—PLCB1—epilepsy syndrome	2.03e-06	2.37e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—ALB—epilepsy syndrome	2.03e-06	2.36e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—TH—epilepsy syndrome	2.03e-06	2.36e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—GPX1—epilepsy syndrome	2e-06	2.33e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—SRC—epilepsy syndrome	1.99e-06	2.32e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—KCNJ11—epilepsy syndrome	1.97e-06	2.29e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—CHRM3—epilepsy syndrome	1.97e-06	2.29e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—FGF2—epilepsy syndrome	1.91e-06	2.23e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—SRC—epilepsy syndrome	1.88e-06	2.19e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—ALB—epilepsy syndrome	1.86e-06	2.17e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—VEGFA—epilepsy syndrome	1.83e-06	2.13e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—AKT1—epilepsy syndrome	1.81e-06	2.1e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—RELA—epilepsy syndrome	1.78e-06	2.07e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—PTGS2—epilepsy syndrome	1.78e-06	2.06e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—AGT—epilepsy syndrome	1.75e-06	2.04e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—APOE—epilepsy syndrome	1.72e-06	2e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—HMOX1—epilepsy syndrome	1.69e-06	1.97e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—AKT1—epilepsy syndrome	1.67e-06	1.94e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—CAT—epilepsy syndrome	1.67e-06	1.94e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—PTGS2—epilepsy syndrome	1.63e-06	1.89e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—ABCG2—epilepsy syndrome	1.6e-06	1.86e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CASP3—epilepsy syndrome	1.6e-06	1.86e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—CYP2C19—epilepsy syndrome	1.56e-06	1.82e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—JUN—epilepsy syndrome	1.56e-06	1.81e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—CYP11A1—epilepsy syndrome	1.55e-06	1.81e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—AKT1—epilepsy syndrome	1.54e-06	1.79e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—MMP9—epilepsy syndrome	1.51e-06	1.76e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—GPX1—epilepsy syndrome	1.51e-06	1.76e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—POMC—epilepsy syndrome	1.48e-06	1.72e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—CYP2D6—epilepsy syndrome	1.4e-06	1.63e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—SRC—epilepsy syndrome	1.4e-06	1.62e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—VEGFA—epilepsy syndrome	1.36e-06	1.58e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—ALB—epilepsy syndrome	1.35e-06	1.57e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—AKT1—epilepsy syndrome	1.34e-06	1.56e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—ADRA2A—epilepsy syndrome	1.33e-06	1.55e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—BCHE—epilepsy syndrome	1.33e-06	1.54e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—AGT—epilepsy syndrome	1.32e-06	1.54e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—APOE—epilepsy syndrome	1.3e-06	1.51e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—SLC2A1—epilepsy syndrome	1.27e-06	1.47e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PLCB1—epilepsy syndrome	1.25e-06	1.46e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—TH—epilepsy syndrome	1.25e-06	1.45e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—AKT1—epilepsy syndrome	1.24e-06	1.44e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—PTGS2—epilepsy syndrome	1.18e-06	1.37e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—AKT1—epilepsy syndrome	1.17e-06	1.36e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—POMC—epilepsy syndrome	1.11e-06	1.3e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—HMOX1—epilepsy syndrome	1.04e-06	1.21e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—CAT—epilepsy syndrome	1.03e-06	1.2e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—ALB—epilepsy syndrome	1.02e-06	1.18e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—ABCB1—epilepsy syndrome	1e-06	1.16e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—GPX1—epilepsy syndrome	9.3e-07	1.08e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—AKT1—epilepsy syndrome	8.92e-07	1.04e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—PTGS2—epilepsy syndrome	8.89e-07	1.03e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—AKT1—epilepsy syndrome	8.68e-07	1.01e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—AKT1—epilepsy syndrome	8.19e-07	9.52e-06	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—AGT—epilepsy syndrome	8.16e-07	9.48e-06	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—APOE—epilepsy syndrome	7.99e-07	9.29e-06	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—POMC—epilepsy syndrome	6.87e-07	7.98e-06	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—ALB—epilepsy syndrome	6.26e-07	7.28e-06	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—AKT1—epilepsy syndrome	5.92e-07	6.88e-06	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PTGS2—epilepsy syndrome	5.48e-07	6.37e-06	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—AKT1—epilepsy syndrome	4.47e-07	5.19e-06	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—AKT1—epilepsy syndrome	2.75e-07	3.2e-06	CbGpPWpGaD
